English | Español

Pharmaceuticals

+ Pharmaceuticals
Patient Daily | Aug 7, 2026

Combination therapy shows efficacy against β-catenin-mutant hepatocellular carcinoma in new study
+ Pharmaceuticals
Patient Daily | Aug 7, 2026

Review examines T cell exhaustion in organ transplantation and its clinical implications
+ Pharmaceuticals
Patient Daily | Aug 7, 2026

Researchers develop new vaccine strategy targeting malaria parasite regions
+ Pharmaceuticals
Patient Daily | Aug 7, 2026

Researchers identify PRDM16 as key regulator in human heart cell development
+ Pharmaceuticals
Patient Daily | Aug 7, 2026

Study finds human skin chemistry drives species-specific mosquito attraction patterns
+ Pharmaceuticals
Patient Daily | Aug 7, 2026

Two-gene interaction linked to metastatic risk in breast cancer, study finds
+ Pharmaceuticals
Patient Daily | Aug 7, 2026

Replimune receives FDA approval for Tudriqev in advanced melanoma after previous rejections
+ Pharmaceuticals
Patient Daily | Aug 7, 2026

Piezo ion channels highlighted as key regulators in digestive health and disease

Trending
+ Pharmaceuticals
Patient Daily | Aug 4, 2026

Merck reports mixed results for tulisokibart in recent clinical trials and financial update
+ Pharmaceuticals
Patient Daily | Aug 6, 2026

FDA approves Replimune’s melanoma drug Tudriqev after advisory committee debate
+ Regulatory
M. Y. Bailey | Aug 7, 2026

PhRMA's Zirkelbach: 340B program has changed dramatically with 'little transparency into how patients benefit'
+ Regulatory
M. R. Armstrong | Aug 4, 2026

Public Policy Solutions on 340B: 'The program has enriched big hospital execs'